Commitment towards creating consistent value for our shareholders
Warning letter received from NSE with regard to corporate announcements submitted in letter head where-in PAN was mentioned.
Press Release - CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK’s MHRA
Completion of US FDA Inspection at Unit V of Apitoria Pharma Private Limited
Retirement of Mrs. Savita Mahajan
Press Release - CuraTeQ Biologics receives positive opinion for biosimilar Zefylti
Order received from the Additional Commissioner (ST), Appellate authority, Vijayawada, Andhra Pradesh
Theranym allotted shares to Dr. Satakarni Makkapati
Press Release - Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg
Clarification on the news appeared in the media on Kakinada Seaport & Kakinada SEZ
Collaboration and License Agreement entered into between a global pharma major and Aurobindo Pharma USA Inc
Press Release - European Medicines Agency (EMA) grants Good Manufacturing Practice (GMP) Certificate of compliance to CuraTeQ
Outcome of Board Meeting – 09.11.2024
Press Release - Hon’ble Prime Minister Shri Narendra Modi Inaugurates Lyfius Pharma’s Flagship Penicillin-G Facility
Acquisition of balance 49% shareholding in GLS Pharma Limited
Disposal of entire 50% shares held in Novagen Pharma (Pty) Ltd., South Africa
Disposal of entire 24.5% shares held in Novagen BBBEE Invest Co (Proprietary) Limited
Press Release - Aurobindo Pharma receives USFDA Approval for Cephalexin Tablets USP, 250 mg and 500 mg
Completion of US FDA Inspection at Unit II of Apitoria Pharma Private Limited
Entered into Agreement with GLS Pharma Limited to acquire balance 49% stake
Eugia Steriles Pvt. Ltd. receives Establishment Inspection Report (EIR) from USFDA
New injectable facility of Eugia Steriles Private Limited receives its first product approval by the US FDA
Order received Deputy Commissioner for reversal of ITC and imposed penalty
Unit III of Eugia Pharma Specialities Ltd. receives Warning Letter from US FDA
Outcome of Board Meeting – 10.08.2024
Press Release - USFDA approval for Estradiol Vaginal Inserts USP, 10 mcg
Classification of US FDA Inspection at Unit II of Eugia Pharma Specialities Ltd.
Outcome of Board Meeting – 18.07.2024 – Buyback
Acquisition of Ace Laboratories Limited, UK
Classification of US FDA Inspection at the injectable facility of Eugia SEZ Pvt. Ltd
Execution of MSA between Merck Sharpe & Dohme Singapore Trading Pte. Ltd. and TheraNym Biologics Pvt.Ltd.
Outcome of Board Meeting – 25.05.2024
Classification of US FDA Inspection at Unit III of Eugia Pharma Specialities Ltd.
Completion of US FDA Inspection at Unit VII of Apitoria Pharma Pvt.Ltd.
Completion of US FDA Inspection at Unit II of Eugia Pharma Specialities Limited.
Purchase of shares held by JV partners in Purple Bellflower Pty Ltd
Order received from Deputy Commissioner for Reversal of ITC and imposed penalty
Completion of Disposal of business assets of Eugia US Manufacturing LLC
A safety accident on April 6 in Unit 6 of Apitoria Pharma Pvt.Ltd.
Completion of US FDA Inspection at the new injectable facility of Eugia Steriles Pvt.Ltd.
Commencement of Commercial Production at four facilities including Penicillin-G
Extension of timeline of LOI between Curateq and MSD upto 31.05.2024
Aurobindo Pharma receives USFDA Approval for Mometasone Furoate Monohydrate Nasal Spray
Press Release - CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product (a biosimilar to Xolair)
Restarting of distribution of aseptic products at Unit III of Eugia Pharma Specialities Ltd
Acceptance of compliance with WHO GMP for APL Healthcare Ltd.
Appointment of Mr.N.Ravikiran as Chief Business Officer
Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg
Restarting of production in terminally sterilized product lines at Unit III of Eugia
Completion of US FDA Inspection at the injectable facility of Eugia SEZ Pvt. Ltd
Completion of US FDA Inspection at synthetic peptide API facility of Auro Peptides Ltd
Aurobindo Pharma receives USFDA Approval for Deflazacort Tablets
Outcome of Board Meeting – 10.02.2024
Record Date for Payment of Second Interim Dividend 2023-24
Disposal of Assets of Eugia US Manufacturing LLC
Completion of US FDA Inspection at Unit III of Eugia Pharma Specialities Ltd
Clarification to Stock Exchange – USFDA inspection in Unit-3 of Eugia
CuraTeQ Biologics receives recommendation for grant of marketing authorization
Classification of US FDA at Unit VI-B as VAI and receipt of EIR
